Unpacking the Latest Options Trading Trends in AbbVie
Unpacking the Latest Options Trading Trends in AbbVie
Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE:ABBV).
資金充裕的投資者對艾伯維(紐交所ABBV)採取看淡態度。
And retail traders should know.
零售交易者應該知道。
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
我們在這裏追蹤的公開期權歷史記錄上看到交易時發現了這一點。
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
無論這些人是機構還是富裕個人,我們並不清楚。但是,當ABBV發生如此重大的事件時,往往意味着有人知道即將發生的事情。
So how do we know what these investors just did?
那麼我們如何知道這些投資者剛剛做了什麼呢?
Today, Benzinga's options scanner spotted 13 uncommon options trades for AbbVie.
今日,Benzinga的期權掃描器發現了13次非常規期權交易,涉及艾伯維公司。
This isn't normal.
這不正常。
The overall sentiment of these big-money traders is split between 23% bullish and 38%, bearish.
這些大金額交易者的整體情緒23%看好和38%看淡。
Out of all of the special options we uncovered, 2 are puts, for a total amount of $195,225, and 11 are calls, for a total amount of $2,536,284.
在我們發現的所有特殊期權中,有2個是看跌期權,總金額爲195,225美元,有11個是看漲期權,總金額爲2,536,284美元。
Projected Price Targets
預計價格目標
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $160.0 to $210.0 for AbbVie during the past quarter.
分析這些合約的成交量和未平倉合約數量,似乎在過去的一個季度中,大型投資者一直關注着一個160.0到210.0美元的價格區間,以期買入艾伯維公司的股票。
Volume & Open Interest Trends
成交量和未平倉量趨勢
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for AbbVie's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across AbbVie's significant trades, within a strike price range of $160.0 to $210.0, over the past month.
分析這些期權的成交量和未平倉量,提供了關鍵的股票研究信息。這些信息對於評估在某些行權價下艾伯維公司的期權的流動性和興趣水平是至關重要的。下面,我們展示了過去一個月內涉及艾伯維公司在160.0到210.0美元行權價區間內的看漲期權和看跌期權的成交量和未平倉量趨勢快照。
AbbVie Option Activity Analysis: Last 30 Days
AbbVie期權活動分析:最近30天
![1724186794_0.png](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240821/42622754-0-15dac3e2a3b6f07f1b663ce1d806002c.png/big)
Biggest Options Spotted:
最大的期權交易:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
ABBV | CALL | TRADE | BULLISH | 06/20/25 | $28.2 | $26.15 | $27.6 | $180.00 | $1.3M | 4.0K | 500 |
ABBV | CALL | TRADE | NEUTRAL | 01/16/26 | $17.75 | $16.25 | $16.95 | $210.00 | $423.7K | 1.8K | 250 |
ABBV | CALL | TRADE | BULLISH | 01/17/25 | $39.15 | $37.5 | $38.79 | $160.00 | $193.9K | 3.1K | 50 |
ABBV | PUT | TRADE | NEUTRAL | 06/20/25 | $17.65 | $16.25 | $17.0 | $200.00 | $170.0K | 65 | 100 |
ABBV | CALL | SWEEP | BEARISH | 03/21/25 | $12.3 | $11.95 | $11.95 | $200.00 | $119.5K | 785 | 102 |
標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
---|---|---|---|---|---|---|---|---|---|---|---|
艾伯維公司 | 看漲 | 交易 | 看好 | 06/20/25 | $28.2 | $26.15 | $27.6 | 180.00美元 | $1.3M | 4.0K | 500 |
艾伯維公司 | 看漲 | 交易 | 中立 | 01/16/26 | $17.75 | $16.25 | $16.95 | 目標股價爲$210.00。 | $423.7K | 1.8K | 250 |
艾伯維公司 | 看漲 | 交易 | 看好 | 01/17/25 | $39.15 | $37.5 | $38.79 | $160.00 | $193.9K | 3.1K | 50 |
艾伯維公司 | 看跌 | 交易 | 中立 | 06/20/25 | $17.65 | $16.25 | $17.0 | 。 | $170.0K | 65 | 100 |
艾伯維公司 | 看漲 | SWEEP | 看淡 | 03/21/25 | $12.3 | 11.95美元 | 11.95美元 | 。 | $119.5K | 785 | 102 |
About AbbVie
關於艾伯維公司
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
AbbVie是一家藥品公司,其在免疫學(包括Humira、Skyrizi和Rinvoq)和腫瘤學(包括Imbruvica和Venclexta)方面擁有強大的業務。該公司於2013年初從Abbott分拆而來。2020年收購雅培使其在美容業務(包括Botox)中新增了一些產品和藥品。
Current Position of AbbVie
艾伯維公司的當前頭寸
- With a volume of 3,625,667, the price of ABBV is down -0.37% at $196.15.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 66 days.
- 成交量爲3,625,667,ABBV的價格下跌0.37%,爲196.15美元。
- RSI因子暗示底層股票可能被超買。
- 下一輪業績預計將在66天后發佈。
What Analysts Are Saying About AbbVie
關於AbbVie,分析師們的看法是什麼
In the last month, 5 experts released ratings on this stock with an average target price of $206.6.
在過去一個月中,有5位專家對這隻股票進行了評級,平均目標價格爲206.6美元。
- An analyst from Wells Fargo persists with their Overweight rating on AbbVie, maintaining a target price of $205.
- Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on AbbVie with a target price of $218.
- Reflecting concerns, an analyst from Truist Securities lowers its rating to Buy with a new price target of $210.
- An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $200.
- An analyst from Barclays persists with their Overweight rating on AbbVie, maintaining a target price of $200.
- 富國銀行的一位分析師堅持給艾伯維公司超配的評級,並保持205美元的目標價格。
- 摩根士丹利的一位分析師在其評估中持續認爲艾伯維公司具有超配的評級,並保持218美元的目標價。
- 受到擔憂的是,Truist Securities的一位分析師將其評級降至買入,並設定了一個新的價格目標爲210美元。
- Cantor Fitzgerald的一位分析師將其評級下調爲超配,並將其價格目標調整爲200美元。
- 巴克萊銀行的一位分析師堅持給艾伯維公司超配的評級,並保持200美元的目標價格。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
期權與僅交易股票相比是一種更具風險的資產,但它們具有更高的利潤潛力。認真的期權交易者通過每日學習,進出交易,跟隨多個指標並密切關注市場來管理這種風險。